Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
At this symposium, the bacterial aetiologies of community-acquired pneumonia and acute exacerbations of chronic bronchitis were evaluated. By reviewing the clinical criteria for the identification of at-risk patients and the recommendations for antimicrobial drug selection in treatment guidelines, the role of levofloxacin in clinical practice was explored. In addition, consideration was also given to the economic impact of using levofloxacin in at-risk patients.
Sollet
Jean-Pierre
JP
D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D064704:Levofloxacin; D015242:Ofloxacin / Q000191:economics / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000453:epidemiology; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D064704:Levofloxacin; D015242:Ofloxacin